Recovering scientist turned early stage VC A biotech optimist fighting gravity

SPR994:  A Long Shot, With Lots Of Twists And Turns To Phase III
May 23, 2019

This blog was written by Ankit Mahadevia, CEO and founder of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC.  At Spero we are privileged to be enrolling our pivotal study for SPR994, our oral antibiotic with

Leave a comment

Biotech Startups And The Hard Truth Of Innovation
May 20, 2019

Gary Pisano’s recent Harvard Business Review piece, The Hard Truth About Innovative Cultures, beautifully frames up how innovative corporate environments are frequently misunderstood. Innovative startups aren’t just about being cool and nimble, having beer taps in the kitchen, or an

Leave a comment

Targeted Protein Degradation Comes of Age
May 15, 2019

This blog was written by Nello Mainolfi, CSO and co-founder of Kymera Therapeutics, as part of the From The Trenches feature of LifeSciVC. Translation of well validated biology into therapeutics remains one of the biggest challenges of modern drug development,

Leave a comment

Getting Clinical On New Drug Launches
May 13, 2019

The IQVIA Institute released a data-rich report in April 2019 on the state of clinical R&D in the US pharmaceutical industry titled “The Changing Landscape of Research and Development: Innovation, Drivers of Change, and Evolution of Clinical Trial Productivity”.  The

Leave a comment

A Decade of Discovery
May 9, 2019

This blog was written by Jeb Keiper, CEO of Nimbus Therapeutics LLC, as part of the From The Trenches feature of LifeSciVC. It is with great excitement that we at Nimbus are ringing in our 10th birthday this month. It’s

Leave a comment

An Encyclopedia Of Advice For Startup Boards
May 6, 2019

Startups management teams often have a love-hate relationship with their Board of Directors: while Boards can be hugely helpful and constructive in the best of times, they can be dysfunctional and damaging in the worst. And most CEOs enjoy complaining

Leave a comment

Maybe It’s Innate
April 30, 2019

This blog was written by Samantha Truex, Atlas EIR and CEO of Quench Bio, as part of the From The Trenches feature of LifeSciVC. Recently I read the article What’s Wrong With Me? that I saw re-posted on Twitter.  It’s

Leave a comment

Why Reputation Is More Important Than Ever For Biotech Companies … And What You Can Do About It
April 24, 2019

This blog was co-written by Deanna Petersen, Chief Business Officer of AVROBIO, and Paul Newman, head of Corporate Communications, as part of the From The Trenches feature of LifeSciVC. “It takes twenty years to build a reputation, and five minutes

Leave a comment

Sheer Heart Attack: What Happens When Your Partner Gets Acquired in The Middle of Negotiations
April 11, 2019

This blog was written by Tariq Kassum, COO of Obsidian Therapeutics, as part of the From The Trenches feature of LifeSciVC. Every morning before I go to work, I review my calendar for the day. This gets me into the

Leave a comment

Cats And The Future Of Machine Learning In Drug Discovery
April 9, 2019

This blog was written by Jonathan Montagu, CEO and founder of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC. The predictions around the impact of artificial intelligence (AI) have been broad reaching but it’s clear that

Leave a comment

Sharing An Innate Desire To Address Inflammation: Novartis and IFM Team Up
April 1, 2019

Today Novartis announced the acquisition of IFM Therapeutics’ portfolio of NLRP3 antagonists, via the purchase of IFM Tre, a subsidiary of IFM (here, here). These immunomodulatory medicines target the inflammasome, a key innate immune node whose pathologic chronic activation is associated with

Leave a comment

Arteaus’ Final Chapter: Monetization Of The Emgality Royalties
April 1, 2019

Back in September 2018, the FDA approved Lilly’s Emgality, an anti-CGRP antibody therapy, for the preventative treatment of episodic and chronic migraine. Arteaus Therapeutics, a biotech company founded by Atlas Venture in 2011, played a critical role in Emgality’s early

Leave a comment